1. Home
  2. ENLV vs INTS Comparison

ENLV vs INTS Comparison

Compare ENLV & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$0.83

Market Cap

26.6M

Sector

Health Care

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.42

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENLV
INTS
Founded
2005
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
24.0M
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
ENLV
INTS
Price
$0.83
$0.42
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$7.00
$4.33
AVG Volume (30 Days)
11.7M
3.2M
Earning Date
11-28-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.79
$0.19
52 Week High
$2.10
$3.17

Technical Indicators

Market Signals
Indicator
ENLV
INTS
Relative Strength Index (RSI) 36.38 47.25
Support Level $0.80 $0.40
Resistance Level $0.88 $0.43
Average True Range (ATR) 0.09 0.06
MACD -0.02 -0.01
Stochastic Oscillator 6.69 20.02

Price Performance

Historical Comparison
ENLV
INTS

About ENLV Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: